<DOC>
	<DOCNO>NCT00721266</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics , maximum tolerate dose anti-tumor activity RO5083945 patient metastatic and/or locally advance malignant EGFR+ solid tumor . In first part study , group patient sequentially enrol receive ascending dos RO5083945 administer weekly , every 2 week every 3 week . The start dose 50mg weekly escalate subsequent group patient successful assessment safety , tolerability pharmacokinetics previous dose . In Part 2 study , patient EGFR+ mutant KRAS colorectal cancer enrol , receive RO5083945 recommend dose regimen identify Part 1 . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Dose-Escalation Study RO5083945 Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor ( EGFR ) + Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; centrally confirm EGFR expression tumor tissue ; radiologically measurable clinically evaluable disease ; last dose systemic antineoplastic therapy radiotherapy &gt; =28 day prior start study ; histologically cytologically confirm advanced stage , primary metastatic EGFR+ solid tumor ( Part 1 ) ; histologically cytologically confirm advanced stage , primary metastatic EGFR+ mutant KRAS colorectal cancer ( Part 2 ) ; 2 previous cytotoxic regimens metastatic disease ( Part 2 ) . history grade 34 toxicity result previous antiEGFR treatment ; know suspect CNS metastasis ; wild type KRAS colorectal cancer ( Part 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>